SUV_mean on baseline [¹⁸F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [¹⁷⁷Lu]Lu-PSMA I&T.

ABSTRACT:

Background

Quantification of [⁶⁸ Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [¹⁸F]-labeled radiotracers, we aimed to determine whether the uptake derived from [¹⁸F]PSMA-1007 PET can also identify responders and to assess its prognostic value relative to established clinical parameters.

Methods

We retrospectively analyzed 103 patients with metastatic, castration-resistant PC who were treated with [¹⁷⁷Lu]Lu-PSMA I&T. We calculated SUV_mean, SUV_max, PSMA-avid tumor volume (TV), and total lesion PSMA (defined as PSMA-TV*SUV_mean) on pre-therapeutic [¹⁸F]PSMA-1007 PET. Laboratory values

SUBMITTER: Hartrampf PE 

PROVIDER: S-EPMC10542708 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature